Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2 - Related Studies

Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2

This study is ongoing, but not recruiting participants.

Study NCT00004067. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Breast Cancer

2	Additional conditions recognized in this trial
		Breast Neoplasms

3	More general conditions related to this trial
		Breast Diseases
		Neoplasms
		Neoplasms by Site
		Skin Diseases

4	Interventions listed in this trial
		cyclophosphamide
		doxorubicin hydrochloride
		paclitaxel
		tamoxifen citrate
		trastuzumab
		endocrine drug therapy
		radiation therapy

5	Additional drug interventions recognized in this trial
		Doxorubicin
		Tamoxifen

6	More general drug interventions related to this trial
		Alkylating Agents
		Antibiotics, Antineoplastic
		Antimitotic Agents
		Antineoplastic Agents
		Antineoplastic Agents, Alkylating
		Antineoplastic Agents, Hormonal
		Antineoplastic Agents, Phytogenic
		Antirheumatic Agents
		Bone Density Conservation Agents
		Estrogen Antagonists
		Estrogen Receptor Modulators
		Hormone Antagonists
		Hormones, Hormone Substitutes, and Hormone Antagonists
		Immunologic Factors
		Immunosuppressive Agents
		Mitosis Modulators
		Molecular Mechanisms of Pharmacological Action
		Myeloablative Agonists
		Pharmacologic Actions
		Physiological Effects of Drugs
		Selective Estrogen Receptor Modulators
		Therapeutic Uses
		Tubulin Modulators

7	Sponsors listed in this trial
		National Surgical Adjuvant Breast and Bowel Project (NSABP)
		National Cancer Institute (NCI)